30 July 2024
Kromek Group plc
("Kromek" or the "Group")
Kromek selected for
First order received under the framework from
Kromek (AIM: KMK), a leading developer of radiation and bio-detection technology solutions for the advanced imaging and CBRN detection segments, is pleased to announce that its D3M detector has been named as the Personal Radiation Detector ("PRD") under the
The Framework is designed to strengthen the
The D3M is the only PRD that has been pre-approved for purchase under the Framework, which is scheduled to be in place for four years. As a result, all blue light service operators in the
Arnab Basu, CEO of Kromek, said: "We are delighted that our D3M detector has been named as the only PRD under this significant
For further information, please contact:
Kromek Group plc |
|
Arnab Basu, CEO Paul Farquhar, CFO |
+44 (0)1740 626 060 |
|
|
Cavendish Capital Markets Limited (Nominated Adviser and Broker) |
|
Geoff Nash/Giles Balleny/Seamus Fricker - Corporate Finance Tim Redfern - ECM |
+44 (0)20 7220 0500
|
Michael Johnson/Tamar Cranford-Smith - Sales
|
|
Gracechurch Group (Financial PR) |
|
Harry Chathli/Claire Norbury/Henry Gamble |
+44 (0)20 4582 3500 |
Kromek Group plc
Kromek Group plc is a leading developer of radiation detection and bio-detection technology solutions for the advanced imaging and CBRN detection segments. Headquartered in
The advanced imaging segment comprises the medical, security and industrial markets. Kromek provides its OEM customers with detector components, based on its core cadmium zinc telluride (CZT) platform, to enable better detection of diseases such as cancer and Alzheimer's, contamination in industrial manufacture and explosives in aviation settings.
In CBRN detection, the Group provides nuclear radiation detection solutions to the global homeland defense and security market. Kromek's compact, handheld, high-performance radiation detectors, based on advanced scintillation technology, are primarily used to protect critical infrastructure and urban environments from the threat of 'dirty bombs'.
The Group is also developing bio-security solutions in the CBRN detection segment. These consist of fully automated and autonomous systems to detect a wide range of airborne pathogens.
Kromek is listed on AIM, a market of the London Stock Exchange, under the trading symbol 'KMK'.
Further information is available at www.kromek.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.